Literature DB >> 12231375

A comparative study of the most widely used solutions for cardiac graft preservation during hypothermia.

Pierre Michel1, Remi Vial, Claire Rodriguez, Rene Ferrera.   

Abstract

BACKGROUND: Reports conflict on the benefits of preservative solutions. We investigated the efficacy of the most widely used cardioplegic solutions by comparing extracellular solutions such as Celsior solution, St. Thomas Hospital solutions 1 and 2 (STH-1, STH-2), the modified University of Wisconsin solution (UW-1), Lyon Preservation solution (LYPS) from our laboratory, and intracellular solutions such as standard University of Wisconsin solution (UW), Bretschneider solution (HTK), Stanford solution (STF), and Euro-Collins solution (EC).
METHODS: Male rats (n = 110) were randomized into 11 groups: LYPS, Celsior, STH-1, STH-2, UW-1, UW, HTK, STF, EC, and normal saline solution groups, and a control group. All hearts, except controls, were preserved by cold storage (8 hours at 4 degrees C) in the various solutions. We used an isolated non-working-heart model and biopsy specimens to assess heart preservation (n = 5/group).
RESULTS: Hearts stored in the EC and saline solutions had poor left ventricular developed pressure (LVDP) x heart rate (HR) (1,407.5 +/- 154 and 1,390 +/- 439 mm Hg/mn, respectively). In contrast, hearts stored in LYPS and Celsior had a LVDP x HR close to control hearts (31,349 +/- 1,847, 27,620 +/- 1,207, and 36,627 +/- 1,322 mm Hg/mn, respectively), whereas hearts stored in STH-1, STH-2, UW-1, UW, HTK, and STF had intermediate functional response (14,278 +/- 2,176, 12,402 +/- 1,571, 11,428 +/- 1,629, 11,603 +/- 2,521, 7,045 +/- 537, and 7,086 +/- 1,206 mm Hg/mn, respectively). Hearts preserved with STH-2, UW, HTK, STF, EC, and saline solution showed significantly increased release of creatine kinase and lactate dehydrogenase than did control hearts or hearts preserved in Celsior, LYPS, STH-1, and UW-1. The energetic charge (EC = [(0.5 adenosine diphosphate + adenosine triphosphate) / (adenosine triphosphate + adenosine diphosphate + adenosine monophosphate)]) in STH-2, UW, HTK, STF, EC, and saline groups was significantly lower (p < 0.05) than in the other groups.
CONCLUSION: Extracellular-type solutions provided better preservation than did intracellular-type solutions. However, UW and UW-1 (intracellular- and extracellular-type solutions) provided equivalent preservation of cardiac function. Preservation quality may be attributed to calcium, often added to extracellular solutions. Among extracellular solutions, Celsior and LYPS solution showed comparable efficacy on left ventricular function and seemed to offer better preservation than the other solutions tested in this study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12231375     DOI: 10.1016/s1053-2498(02)00414-x

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

Review 1.  Principles of low temperature cell preservation.

Authors:  Boris Rubinsky
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

2.  Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study.

Authors:  Francisco A García-Gil; María T Serrano; Lorena Fuentes-Broto; Juan Arenas; José J García; Antonio Güemes; Vanesa Bernal; Ana Campillo; Carlos Sostres; Juan J Araiz; Pablo Royo; Miguel A Simón
Journal:  World J Surg       Date:  2011-07       Impact factor: 3.352

3.  Low-flow perfusion of guinea pig isolated hearts with 26 degrees C air-saturated Lifor solution for 20 hours preserves function and metabolism.

Authors:  David F Stowe; Amadou K S Camara; James S Heisner; Mohammed Aldakkak; David R Harder
Journal:  J Heart Lung Transplant       Date:  2008-07-26       Impact factor: 10.247

4.  Myocardial protection in on-pump coronary artery bypass grafting surgery: analysis of the effectiveness of the use of retrograde Celsior®.

Authors:  José López-Menéndez; Javier Miguelena; Carlos Morales; Francisco Callejo; Jacobo Silva
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.